Department of Neurology, University Hospital of Munich, LMU Munich, Munich, Germany.
German Center for Neurodegenerative Diseases (DZNE), Munich, Germany.
Eur J Nucl Med Mol Imaging. 2023 Jan;50(2):423-434. doi: 10.1007/s00259-022-05964-w. Epub 2022 Sep 14.
Early after [F]PI-2620 PET tracer administration, perfusion imaging has potential for regional assessment of neuronal injury in neurodegenerative diseases. This is while standard late-phase [F]PI-2620 tau-PET is able to discriminate the 4-repeat tauopathies progressive supranuclear palsy and corticobasal syndrome (4RTs) from disease controls and healthy controls. Here, we investigated whether early-phase [F]PI-2620 PET has an additive value for biomarker based evaluation of 4RTs.
Seventy-eight patients with 4RTs (71 ± 7 years, 39 female), 79 patients with other neurodegenerative diseases (67 ± 12 years, 35 female) and twelve age-matched controls (69 ± 8 years, 8 female) underwent dynamic (0-60 min) [F]PI-2620 PET imaging. Regional perfusion (0.5-2.5 min p.i.) and tau load (20-40 min p.i.) were measured in 246 predefined brain regions [standardized-uptake-value ratios (SUVr), cerebellar reference]. Regional SUVr were compared between 4RTs and controls by an ANOVA including false-discovery-rate (FDR, p < 0.01) correction. Hypoperfusion in resulting 4RT target regions was evaluated at the patient level in all patients (mean value - 2SD threshold). Additionally, perfusion and tau pattern expression levels were explored regarding their potential discriminatory value of 4RTs against other neurodegenerative disorders, including validation in an independent external dataset (n = 37), and correlated with clinical severity in 4RTs (PSP rating scale, MoCA, activities of daily living).
Patients with 4RTs had significant hypoperfusion in 21/246 brain regions, most dominant in thalamus, caudate nucleus, and anterior cingulate cortex, fitting to the topology of the 4RT disease spectrum. However, single region hypoperfusion was not specific regarding the discrimination of patients with 4RTs against patients with other neurodegenerative diseases. In contrast, perfusion pattern expression showed promise for discrimination of patients with 4RTs from other neurodegenerative diseases (AUC: 0.850). Discrimination by the combined perfusion-tau pattern expression (AUC: 0.903) exceeded that of the sole tau pattern expression (AUC: 0.864) and the discriminatory power of the combined perfusion-tau pattern expression was replicated in the external dataset (AUC: 0.917). Perfusion but not tau pattern expression was associated with PSP rating scale (R = 0.402; p = 0.0012) and activities of daily living (R = - 0.431; p = 0.0005).
[F]PI-2620 perfusion imaging mirrors known topology of regional hypoperfusion in 4RTs. Single region hypoperfusion is not specific for 4RTs, but perfusion pattern expression may provide an additive value for the discrimination of 4RTs from other neurodegenerative diseases and correlates closer with clinical severity than tau pattern expression.
在 [F]PI-2620 示踪剂给药后早期,灌注成像有可能对神经退行性疾病中的神经元损伤进行区域评估。而标准的晚期 [F]PI-2620 tau-PET 能够将 4 重复 tau 病进行性核上性麻痹和皮质基底节综合征(4RTs)与疾病对照和健康对照区分开来。在这里,我们研究了早期 [F]PI-2620 PET 是否对基于生物标志物的 4RT 评估具有附加价值。
78 名 4RTs 患者(71±7 岁,39 名女性)、79 名其他神经退行性疾病患者(67±12 岁,35 名女性)和 12 名年龄匹配的对照者(69±8 岁,8 名女性)接受了动态(0-60 分钟)[F]PI-2620 PET 成像。在 246 个预先定义的脑区(标准化摄取值比(SUVr),小脑参考)中测量了局部灌注(0.5-2.5 分钟 p.i.)和 tau 负荷(20-40 分钟 p.i.)。通过包括错误发现率(FDR,p<0.01)校正的方差分析,比较 4RTs 和对照组之间的区域 SUVr。在所有患者中(平均值-2SD 阈值),在患者水平评估导致的 4RT 靶区的低灌注。此外,还探讨了灌注和 tau 模式表达水平对 4RTs 与其他神经退行性疾病的潜在鉴别价值,包括在独立的外部数据集(n=37)中的验证,并与 4RTs 的临床严重程度(PSP 评分、MoCA、日常生活活动)相关。
4RTs 患者的 21/246 个脑区有明显的低灌注,最明显的是丘脑、尾状核和前扣带回,与 4RT 疾病谱的拓扑结构相符。然而,单个区域的低灌注对于将 4RTs 患者与其他神经退行性疾病患者区分开来并不具有特异性。相比之下,灌注模式表达对于将 4RTs 患者与其他神经退行性疾病患者区分开来具有很大的潜力(AUC:0.850)。联合灌注-tau 模式表达的鉴别(AUC:0.903)优于单独的 tau 模式表达(AUC:0.864),联合灌注-tau 模式表达的鉴别能力在外部数据集中得到了复制(AUC:0.917)。灌注而不是 tau 模式表达与 PSP 评分(R=0.402;p=0.0012)和日常生活活动(R=-0.431;p=0.0005)相关。
[F]PI-2620 灌注成像反映了 4RTs 中已知的区域性低灌注的拓扑结构。单个区域的低灌注对 4RTs 不具有特异性,但灌注模式表达可能为 4RTs 与其他神经退行性疾病的鉴别提供附加价值,并且与临床严重程度的相关性比 tau 模式表达更密切。